Background
Alpinia oxyphylla belongs to the
Zingiberaceae family and is widely cultivated in Asia as one of the most frequently used plant extracts in oriental medicine. The most well-known medicinal effect of
A. oxyphylla includes enhancing the internal and astringent activities of the kidney and spleen [
1]. Recent studies have shown that
A. oxyphylla possesses a wide range of pharmacological activities, such as anti-diabetes [
2], anti-fibrosis [
3], anti-diarrheal [
4], and anti-cancer [
5].
A. oxyphylla contains various chemical constituents, including essential oils, sesquiterpenes, flavones, diarylheptanoids, glycosides and steroids. Amongst them, nootkatone is one of the more abundant components [
6]. Nootkatone has also been identified as the main fragrant component of grapefruit with a wide range of beneficial effects including anti-inflammation activities [
7], AMPK activation [
8] and neuroprotective effects [
9]. Other bioactive compounds in
A. oxyphylla, yakuchinone A [
10] and yakuchinone B [
11], are also known to have several biological activities including anti-cancer activity. However, the molecular target of nootkatone and other bioactive compounds in cancer or in cell proliferation is unknown.
By analyzing identified molecular targets of phytochemicals, we discovered that the nonsteroidal anti-inflammatory drug [NSAID]-activated gene-1 (NAG-1, also known as GDF15) is highly induced by several phytochemicals [
12]. Ectopic expression of NAG-1 causes cell growth arrest, and overexpression of NAG-1 in human colon cells results in reduced tumor formation in the nude mouse model [
13]. Although in vitro assays show contradictory results, studies conducted in NAG-1 TG and NAG-1 KO mice consistently demonstrate a clear association between NAG-1 expression and tumor suppression [
14]. Thus, NAG-1 induction is a likely molecular mechanism for anticancer activity induced by phytochemicals.
Cyclin D1, another common target of phytochemicals, is often overexpressed in various cancer cell types and tumors. In addition to its role in the cell cycle, cyclin D1 functions as a critical regulator of DNA repair, and thus constitutes a key molecular regulator of transcription [
15]. A large number of anticancer chemicals have been shown to downregulate cyclin D1 in various cancer cell types by triggering multiple signaling pathways [
16].
EGR-1 is induced very early in the apoptotic process, and mediates the activation of downstream regulators such as p53 [
17]. However, EGR-1-induced apoptosis has also been reported in p53
−/− cells, indicating the existence of both p53-dependent and p53-independent pathways. EGR-1 also activates tumor suppressor gene phosphatase and tensin homolog (PTEN) during UV irradiation and suppresses the growth of transformed cells both in soft agar and in athymic nude mice [
18]. While these results indicate that EGR-1 plays a significant role in growth suppression, the consequences of EGR-1 expression may vary depending on the cellular context. Discrepancies in its role may depend on expression levels of other EGR-1 family members, Sp1, EGR-1 binding repressors, or other factors yet to be identified. Interestingly, EGR-1 has been linked to increased NAG-1 promoter activity, mediated by nonsteroidal anti-inflammatory drugs [
19].
Thus, NAG-1, cyclin D1, or EGR-1 could be a molecular target of many bioactive compounds that could lead to anti-proliferation activity. The identification of the molecular target of nootkatone may lead to the development of better single compounds for cancer therapy.
In this study, we identified the biological activity of A. oxyphylla and its major compound nootkatone as an inducer of the pro-apoptotic protein NAG-1 and a suppressor of cyclin D1, thereby inhibiting cell proliferation in colon cancer cells. Further, the mechanism by which nootkatone affects cyclin D1 and NAG-1 has been studied. Our results indicated that EGR-1 plays a pivotal role in nootkatone-induced NAG-1 expression, while the proteosomal degradation pathway contributes to nootkatone-mediated cyclin D1 downregulation.
Methods
Reagents
A. oxyphylla was purchased from Kyung-Dong Market in Seoul, Korea. The authenticity was confirmed at least twice through morphological analysis by Dr. Jaeyoon Cha, Department of Food Science and Nutrition, Dong-A University, Busan, Republic of Korea. A voucher specimen (No. EHNP-H8) has been deposited in the R&D Center, EastHill Corporation, Suwon, Gyeonggi-do, Republic of Korea. The plants were washed and ground using a laboratory mill to a particle size of 100 mesh. Ethanol (70%) was added to the ground plants and extracted at 70 °C for 48 h with stirring at 500 rpm. The extract was filtered using Toyo No. 4 filter paper and concentrated using a vacuum evaporator. Finally, the concentrate was diluted in dimethyl sulfoxide to obtain a final concentration 100 mg/mL. Nootkatone was purchased from Tokyo Chemical Industry (Tokyo, Japan). Epoxomicin and Puromycin (P8833–10) were purchased from Sigma Aldrich (St. Louis, MO, USA) and MG132 was purchased from AdooQ® Bioscience (Irvine, CA, USA). Antibodies for Cyclin D1 (sc-753), HRP conjugated β-actin (sc-47,778), and p53 (sc-126) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Antibody for NAG-1 was previously described [
13].
Cell culture
All cells used in this study were purchased from American Type Culture Collection (ATCC). Cells were tested by ATCC for post-freeze viability, growth properties, morphology, mycoplasma contamination, species determination (cytochrome c oxidase I assay and short tandem repeat analysis), sterility test and human pathogenic virus testing. Upon arrival, cell lines were straightaway resuscitated and frozen in aliquots in liquid nitrogen. HCT-116 (Human colorectal carcinoma) and HT-29 (Human colorectal adenocarcinoma) cells were cultured using McCoy’s 5A media (Gibco life technologies, Carlsbad, CA, USA). SW480 (Human colorectal adenocarcinoma), DLD-1 (Human colorectal adenocarcinoma) were cultured using RPMI-1640 media (GIBCO). Both McCoy’s 5A media and RPMI-1640 media contained 10% Fetal bovine serum (FBS; GIBCO) and 1% penicillin/streptomycin (GIBCO). All cells were maintained at 37 °C and 5% CO2.
Plasmid transfection and luciferase assay
The promoter-luciferase constructs pNAG1–1086/+ 41, pNAG1–474/+ 41, and pNAG1–133/+ 41 were previously described [
12]. The expression vector pcDNA-EGR-1 has also been described [
19]. The luciferase and pRL-null plasmids were transfected into cells using PolyJet™ In Vitro DNA Transfection reagent (SignaGen, Frederick, MD, USA) according to manufacturer’s instructions. Luciferase activity was measured using Dual-Luciferase® Reporter Assay kit (Promega, WI, USA) as previously described [
20].
Both HCT-116 and SW480 cells were seeded at a density of 1 × 104 cells/well in 6-well culture plates. Cells were treated with nootkatone at various doses (10 μM, 50 μM, or 100 μM) for 9 days. The culture media containing indicated concentrations of nootkatone were changed every 3 days. After treatment, the plate was washed with phosphate-buffered saline, and cells were fixed with 4% paraformaldehyde (Biosesang, Gyeonggi-do, Korea), followed by staining with 1% crystal violet solution (V5265, Sigma Aldrich). The number of colonies was counted using Image J software 1.52a (National Institutes of Health, MD, USA).
Western blot analysis
Western blot analysis was conducted as previously described [
21]. Briefly, 50 μg proteins were separated using 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (GVS filter technology, Zola Predosa BO, Italy). The blotted membrane was then blocked with 5% skim milk for 1 hr at room temperature and incubated overnight with specific antibodies at 4 °C. After incubation with HRP conjugated secondary antibody in 5% skim milk for 1 hr at room temperature, the blotted membranes were visualized using the Alliance Q9 mini imaging system (Cambridge, UK) and quantified using ImageJ software 1.52a (National Institutes of Health, MD, USA).
RNA isolation and reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Five hundred nanograms of total RNA was used to synthesize cDNA using Verso cDNA Synthesis kit (Thermo scientific, Waltham, MA, USA). PCR products were amplified using the following primer pairs: cyclin D1 (F: 5′-CAA TGA CCC CGC ACG ATT TC-3′, R: 5′-AAG TTG TTG GGG CTC CTC AG-3′), NAG-1 (F: 5′-CTC CAG ATT CCG AGA CTT GC-3′, R:5′-AGA CAT ACG CAG GTG CAG GT-3′), GAPDH (F: 5′-GAC CAC AGT CCA TGC CAT CAC T-3′, R: TCC ACC ACC CTG TTG CTG TAG-3′). Thermal cycling conditions for NAG-1 were as follows: initial denaturation at 95 °C for 2 min, followed by 25–35 cycles of 94 °C for 30 s, 53.2 °C for 30 s, and 72 °C for 1 min, and final elongation at 72 °C for 5 min. For cyclin D1 and GAPDH, amplification and annealing temperatures were set to 52.5 °C and 60 °C respectively. PCR products were electrophoresed on a 1.5% agarose gel and photographed using the Alliance Q9 mini imaging system.
Cell proliferation assay
HCT-116 and SW480 were seeded in 96-well plates (1 × 103 cells/well for HCT-116 cells and 2 × 103 cells/well for SW480 cells) and incubated for 24 h with 100 μL of complete medium. Different dose of A. oxyphylla was treated for the indicated time. Cell proliferation assays were then performed using CellTiter 96® AQueous One Solution (Promega, WI, USA) according to the manufacturer’s instructions. After indicated time of culture, 20 μL of One Solution reagent was added to each well and cells were incubated for 1 h at 37 °C. Cell viability was estimated by measuring the absorbance at 492 nm using Multiskan FC spectrophotometer (Thermo Fisher Scientific, Waltham, MA).
Antioxidant activity assay
The 2,2-diphenyl-1-picrylhydrazyl (DPPH, #14805, Cayman Chemical, MI, USA) and 2,2 -azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS, #A1888, Sigma Aldrich) were used for the radical scavenging assay, as previously described [
22]. The absorbance was measured using a Multiskan™ FC microplate photometer (Thermo Fisher Scientific, Waltham, MA). L-ascorbic acid (#A0537, TCI, Tokyo, Japan) was used as a reference standard in both assays. Determination of the percentage of radical scavenging effect was considered using the following equation:
$$ \%\mathrm{Inhibition}=100-\left[\left(\mathrm{Absorbance}\ \mathrm{of}\ \mathrm{sample}-\mathrm{Absorbance}\ \mathrm{of}\ \mathrm{blank}\right)\times 100/\mathrm{Absorbance}\kern0.5em \mathrm{of}\kern0.5em \mathrm{control}\right]. $$
The VCEAC for ABTS assay and the IC50 value were calculated as half the concentration of the sample that can scavenge 50% of the DPPH free radical.
Spheroid assay
Seven hundred and fifty HCT-116 cells were seeded in an ultra-low attachment round bottom 96-well plate (Coster, Kennebunk, ME, USA), and cultured for 4 days. After spheroids were formed, half of the media was replaced with complete media containing 2 times the required dosage of nootkatone, and spheroids were incubated for 3 days. Spheroid viability was measured by the CellTiter-Glo® 3D Cell Viability Assay (Promega, Madison, WI, USA) in accordance with the manufacturer’s instuctions. Spheroid volume was calculated using the following formula: 0.5 × Length × Width2.
Discussion
Plant extracts and its bioactive compounds have been studied in cancer research. Recent data also suggested the usage of plant derived compounds in new generation immunotherapeutic vaccine [
24].
A. oxyphylla possesses a wide range of biological activities, including anti-diabetes, anti-liver fibrosis, antidiarrheal, and neuronal protection effects [
1]. Moreover, several publications have reported anticancer effects of
A. oxyphylla such as in liver cancer cells via AKT pathway suppression [
5]. Our findings further confirm its anti-proliferative activity in colorectal cancer cells. Nootkatone is one of nine bioactive compounds found in
A. oxyphylla [
6], and showed ability to inhibit the expression of inducible nitric oxide synthase (iNOS) and reduce NO production in lipopolysaccharide (LPS) stimulated RAW264.7 cells [
25]. Additionally, nootkatone increased survival rates in septic mice by increasing HO-1 expression [
25]. Although nootkatone has been linked to anticancer activity in lung cancer via the AMPK pathway [
8], the effects of nootkatone against colorectal cancer and its mechanisms underlying these effects remain unknown.
Metastatic cancer encompasses a diverse collection of cells that possess different genetic characteristics and are controlled by many proteins [
26‐
28]. It is also suggested that autophagy plays a role in metastasis [
29]. Nootkatone inhibits protein expression that are involved in metastatic cancer and induces autophagy [
30]. Thus, molecular elucidation of nootkatone in anti-tumorignesis may lead to better understanding of cancer treatment in metastatic cancer treatment.
In this report, we show that nootkatone treatment contributes to inhibition of cell proliferation in colorectal cancer cells. Our results also suggest that cyclin D1 suppression and NAG-1 induction may at least in part be mechanistically involved in nootkatone-induced anti-tumorigenic activity.
The suppression of cyclin D1 and induction of NAG-1 by nootkatone were observed at a concentration of 100 μM. A similar result was reported in lung cancer cells where 100 μM of nootkatone was required to obtain cell growth inhibition [
8]. Since the systemic concentration of nootkatone and its concentration in tissues has not been reported, and most phytochemicals could reach even higher concentrations in the gastrointestinal (GI) track, the speculation that nootkatone probably reaches 100 μM in the GI track is reasonable. Therefore, the large intestinal epithelia, including colon and rectum, could be highlighted as a logical target tissue to further explore nootkatone as an anti-cancer treatment. Additionally, since nootkatone is bio-transformed to various metabolites by fungal strains, the impact of specific nootkatone metabolites may be of particular interest in future cancer studies [
31]. In this regard, nootkatone metabolites should be considered as an important compound with respect to cancer progression. A number of reports suggest that cyclin D1 could be a target for many phytochemicals since cyclin D1 downregulation is common in various phytochemical-treated samples [
32,
33]. Most phytochemicals affect cyclin D1 at the protein level, as was confirmed in the current study regarding nootkatone’s effects on cyclin D1 protein. Similarly, DIM, EGCG, damnacanthal, and 6-ginerol downregulates cyclin D1 post-translationaly, thereby accounting for the anti-tumorigenic activity of these compounds [
16,
32‐
34]. Cyclin D1 controls many pathways in addition to the cell cycle [
35], suggesting that the benefits of cyclin D1 inhibition in cancer may result from several mechanisms.
Transcriptional regulation of NAG-1 is modulated by several
cis- and
trans-acting elements [
12]. The 133 bp promoter region of NAG-1 contains several transcriptional binding sites, including C/EBPβ [
36], p53 [
37], EGR-1 [
19], and Sp1 [
12]. These transcription factors are responsible for the downstream effects of several anticancer compounds including COX inhibitors, PPARγ ligands and cancer chemo-preventive agents [
38] which increase NAG-1 transcription. Interestingly, sulindac sulfide (or troglitazone)-mediated NAG-1 up-regulation is dependent on the transcription factor EGR-1 in colon cancer cells [
39]. EGR-1 binding sites have been detected in the NAG-1 promoter, overlapping the Sp1 binding site. Here, we report that nootkatone increases EGR-1 both at the protein level as well as at the transcriptional level in colorectal cancer cells, and facilitates NAG-1 promoter activity. This suggests that EGR-1 may be responsible for nootkatone -mediated NAG-1 up-regulation. Since PPARγ ligand troglitazone also increases EGR-1 expression, we examined whether nootkatone may affect PPARγ transcriptional factors. As expected, nootkatone treatment increased PPARγ binding activity as assessed using a reporter construct bearing the PPAR response element (data not shown). Nonetheless, PPARγ activation may not be involved in nootkatone-induced NAG-1 expression at the transcriptional level. Since the emerging pieces of evidence indicate that repurposing of drugs is crucial to the faster and cheaper discovery of anti-cancerous drugs [
40], nootkatone should be seriously considered for the design of future cancer drugs.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.